Trial Design Likely Boosted Biogen (BIIB) BIIB037 Efficacy Data - Nomura

UPDATE: Stifel Downgrades Biogen (BIIB) to Hold

(Updated - March 23, 2015 11:30 AM EDT)

Stifel downgraded Biogen (NASDAQ: BIIB) from Buy to Hold and removed its price target (prior $451.00). Last week Biogen excited Wall Street when it reported positive data from its Phase 1b study of aducanumab (BIIB037) in Alzheimers disease. Analyst Thomas Shrader noted definitive data is still years away. He also noted safety could be an issue.

"Despite our belief that Biogen Idec is in the drivers seat in neurological drug development at a highly productive time in this... More

Biogen (BIIB) Price Target Lifted to $532 at Leerink Partners on Strong Showing for BIIB037

Leerink Partners analyst Joseph Schwartz reiterated an Outperform rating and lifted his price target on Biogen (NASDAQ: BIIB) to $532.00 (from $475.00)

Schwartz said, "This morning at the ADPD15 meeting, BIIB reported better than expected results from BIIB037s Ph. Ib trial on both... More

Biogen (BIIB) PT Lifted to $512 at Citi; Questions Remain on Dose/Saftey

Citi reiterated a Buy rating and boosted its price target on Biogen (NASDAQ: BIIB) to $512.00 (from $410.00) following solid potency data on BIIB037, although main question in dose/safety.

"The only question is safety as 32% of patients on the high does... More

Biogen (BIIB) PT Raised to $500 at Cowen Amid BIIB037 Data

Cowen analyst Eric Schmidt reiterated an Outperform rating and raised his price target on Biogen (NASDAQ: BIIB) to $500.00 (from $425.00) following BIIB037 data.

commented, "BIIB037 (aducanumab) demonstrated an impressive time and dose dependent reduction in decline of cognition as measured on MMSE (76%... More

Biogen (BIIB) PT Raised to $500 at Barclays on 'Impressive' AD Data

Barclays analyst Geoffrey Meacham reiterated an Overweight rating and boosted his price target on Biogen (NASDAQ: BIIB) to $500.00 (from $435.00) following "impressive' AD data.

"The data provided quantitative evidence of a statistically significant benefit vs placebo at 54 weeks on key connotative endpoints...",... More

Biogen (BIIB) BIIB-037 Data Shows Strong Efficacy, Very Good Safety, Says RBC

RBC Capital maintained an Outperform rating on Biogen (NASDAQ: BIIB) with a price target of $445. Comments follow the release of BIIB-037 data in Alzheimers disease. Analyst Michael J. Yee noted data showed strong efficacy and very good safety.

"We are at the AD/PD conf in Europe & there are a few... More

Biogen Idec (BIIB) Reports Statistically Significant Data from Aducanumab Phase 1b

Biogen Idec (NASDAQ: BIIB) announced data from a pre-specified interim analysis of PRIME, the Phase 1b study of aducanumab (BIIB037), in which aducanumab demonstrated an acceptable safety profile and positive results on radiologic and clinical measurements in patients with prodromal or mild Alzheimers disease (AD). These data are being presented today at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders in Nice, France.

Treatment with aducanumab produced a dose- and time-dependent reduction of amyloid plaque in the brain. Amyloid plaque is... More